AAVantgarde · 1 day ago
Associate Director, Surgical/Medical Science Liaison - Ophthalmology
AAVantgarde Bio is focused on advancing clinical and medical strategies in gene therapy and inherited retinal diseases. The Associate Director will oversee surgical training, ensure trial site readiness, and coordinate medical affairs activities while building relationships with key stakeholders.
BiotechnologyHealth CareLife ScienceTherapeutics
Responsibilities
Ensure surgical readiness at trial sites
Offer hands-on training and support to surgical and pharmacy teams
Monitor procedures to ensure protocol adherence
Troubleshoot logistic challenges related to the surgical procedure
Refine training materials in collaboration with the Director of Surgical Liaison
Coordinate medical affairs activities such as advisory boards and congress engagements
Foster relationships with key opinion leaders, surgeons, academic institutions, and patient representatives
Shape the strategic direction of clinical programs and ensure alignment with regulatory and ethical standards
Qualification
Required
Strong background in Ophthalmology and medical affairs
Prior experience in surgical training or medical affairs within the pharmaceutical or biotechnology industry
Exposure to Phase I/II clinical trials involving ocular surgical procedures
Medical degree (MD), PhD, PharmD, or B.Optometry
Practical, solution-oriented mindset
Ability to thrive in a fast-paced, evolving environment
Proven track record in delivering hands-on training—both dry and wet lab formats—to surgeons and pharmacists
Comfortable working within an operating room setting
Strong communication and stakeholder management skills
Ability to build lasting relationships with key opinion leaders and clinical partners
Familiarity with US regulatory frameworks
Prior experience in a start-up environment
Flexibility and enthusiasm for fieldwork
Significant travel (>50%)
Company
AAVantgarde
AAVantgarde is a clinical stage, biotechnology company advancing best-in-class therapies for patients with inherited retinal diseases (IRDs).
Funding
Current Stage
Growth StageTotal Funding
$206.25MKey Investors
Sofinnova Partners
2025-11-03Series B· $141M
2023-06-06Series A· $65.25M
2021-06-30Seed
Recent News
2025-11-19
Company data provided by crunchbase